Show simple item record Xavier, Melissa Orzechowski Pasqualotto, Alessandro Comarú Aquino, Valério Rodrigues SukiennikI, Teresa Cristina Teixeira Severo, Luiz Carlos 2012-10-08T12:51:14Z 2012-10-08T12:51:14Z 2009
dc.identifier.citation XAVIER, Melissa Orzechowski et al. Galactomannan detection from piperacillin-tazobactam brands available in the brazilian market. Brazilian Journal of Infectious Diseases, v. 13, n. 5, p. 353-355, 2009. Disponível em: <>. Acesso em: 29 set. 2012. pt_BR
dc.description.abstract Piperacillin-tazobactam is a broad spectrum antimicrobial agent that can cause false-positive results in the commercial Platelia Aspergillus EIA test. So far, no study has been performed in Latin America to evaluate the clinical implication of this finding. Here we studied the potential for galactomannan detection in piperacillintazobactam batches commercialized in the Brazilian market. Five batches from distinct laboratories were tested in duplicate in the Platelia Aspergillus EIA according to the manufacturer’s instructions. Only one drug showed crossreaction at a cut-off of 0.5. Human serum was spiked with this particular drug aiming to mimic achievable piperacillintazobactam concentrations in the serum. Results were all negative for galactomannan detection, even at high drug concentrations. Results from this pilot study suggest that piperacillin-tazobactam might not be a clinically significant cause of false-positive results in the Platelia Aspergillus EIA test in Brazil. pt_BR
dc.language.iso eng pt_BR
dc.rights open access pt_BR
dc.subject Piperacillin-tazobactam pt_BR
dc.subject Aspergillosis pt_BR
dc.subject Platelia aspergillus pt_BR
dc.subject Galactomannan pt_BR
dc.title Galactomannan detection from piperacillin-tazobactam brands available in the brazilian market pt_BR
dc.type article pt_BR
dc.identifier.doi pt_BR

Files in this item

This item appears in the following Collection(s)


  • FAMED – Artigos publicados em periódicos
  • Show simple item record